We are committed to embedding sustainability into all aspects of our operations, creating long-term value for our investors and stakeholders. Building on the substantial initiatives of the previous years and with reference to the latest sustainability standards, we developed a holistic sustainability framework covering areas that are central to our industry – climate action, innovation, […]
View 2023 Report 1. ABOUT THIS REPORT 3 2. 2023 SUSTAINABILITY HIGHLIGHTS 4 3. MESSAGE FROM OUR CHAIRMAN 7 4. ABOUT HUTCHMED 9 5. SUSTAINABILITY GOVERNANCE 15 Sustainability Governance Structure 16 Risk Management 19 Sustainability & Governance Policies 21 6. SUSTAINABILITY STRATEGY 22 Stakeholder Engagement Approach 22 Developing a Holistic Sustainability Strategy 27 7. BUSINESS […]
Date: Friday, May 10, 2024 Time: 5:00 pm Hong Kong Time (10:00 am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong
Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 8, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2023 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”), will be posted on April 9, 2024 to those shareholders who have elected […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, April 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in […]
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent […]
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and expand indication to more patients — Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 28, 2024: HUTCHMED (China) […]
PRINCIPAL SHARE REGISTRAR Computershare Investor Services (Jersey) Limited 13 Castle Street, St. Helier Jersey, Channel Islands JE1 1ES Telephone: +44 (0)370 707 4040 Facsimile: +44 (0)370 873 5851 HONG KONG BRANCH SHARE REGISTRAR Computershare Hong Kong Investor Services Limited Shops 1712-1716, 17th Floor Hopewell Centre, 183 Queen’s Road East Wanchai, Hong Kong Telephone: +852 2862 […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. This follows positive data from the proof-of-concept […]
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, March 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options (“Share Options”) under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share Option Scheme”) and awards (“LTIP Awards”) under the Long Term Incentive Plan […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2023 annual results of HUTCHMED on February 28, 2024, the following awards granted under the Long Term Incentive Plan (“LTIP”) on March 26, 2021 to Dr Weiguo Su and […]
Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 28, 2024: HUTCHMED […]
Announcement release: Feb 28, 2024 (Wed) 6:30am EST / 11:30am GMT / 7:30pm HKT >> View announcement here << Presentation webcast & call ⯈ English Session: Feb 28, 2024 (Wed) 7:30am EST / 12:30pm GMT / 8:30pm HKT Listen to the webcast replay (English Session) ⯈ Chinese (Putonghua) Session: Feb 29, 2024 (Thu) 7:30pm EST […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (“ASCO”) Plenary […]
Hong Kong, Shanghai & Florham Park, NJ — Friday February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the “Options”) pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, February 1, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong […]
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in […]
Job Title: Sales Director / Associate Sales Director Location: Hong Kong Responsibilities Execute company strategies and achieve sales targets within budgets and timescales; Build and maintain a good and sustainable partnership with medical and pharmaceutical professionals; Fulfill the guidelines of internal company policies (e.g. Anti Bribery and Anti Corruption Policy, Code of Ethics etc.); Prepare […]
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — Hong Kong, Shanghai & Florham Park, NJ — Thursday, […]
Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at December 29, 2023, the issued share capital of HUTCHMED consisted of 871,256,270 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no […]
Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: (a) Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option […]
In anticipation of the expiration of the initial terms of the Framework Sinopharm Products Supply and Purchase Agreement and the HBYS Brand License Royalty Agreement on December 31, 2023, on December 21, 2023: the Company and Sinopharm agreed to renew the Framework Sinopharm Products Supply and Purchase Agreement with effect from January 1, 2024 for […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The study is a […]
Job Title: (Senior/Principal) Clinical Research Physician Location: Shanghai Primary Function Provide medical monitoring for clinical studies. Provide medical leadership on project teams. Participates in development of the Clinical Development (CD) strategy and plan and supports the assigned Medical Director/AD with various deliverables necessary for effective and efficient CD plan execution for the assigned molecule(s)/indication(s). Support […]
On December 7, 2023, the Seller (a wholly-owned subsidiary of the Company) and HWCL (an indirect subsidiary of CK Hutchison) entered into the Share Sale and Purchase Agreement relating to the disposal by the Seller of its interest in the Consumer Products Businesses for an aggregate purchase price of HK$39.8 million (US$5.1 million). Closing […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 1, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Asia Congress, taking place on […]
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, November 30, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at November 30, 2023, the issued share capital of HUTCHMED consisted of 871,172,770 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no […]
Date: Thursday, Nov 9, 2023 Time: 8:30am ET / 1:30pm GMT/ (9:30pm HKT ) Listen to the Webcast
— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 24, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 20, 2023:- Award Holder Number of […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on […]
Hong Kong, Shanghai, & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 29, 2023, the issued share capital of HUTCHMED consisted of 871,035,940 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no […]
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in […]
We take your privacy very seriously and are committed to being transparent with how we use Personal Data. This Privacy Notice (this “Privacy Notice”) sets out how HUTCHMED (China) Limited and its subsidiaries and affiliates (“HUTCHMED,” “we,” “us,” and/or “our”) collect, use, share , and otherwise process information that may identify you (your “Personal Data”) […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, September 14, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) has received notifications that the spouse of Mr Graeme Jack, Independent Non-executive Director, sold a total of 3,000 American Depositary Shares of the Company (“ADSs”, each representing five Ordinary Shares of US$0.10 each […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration non-small cell lung cancer (“NSCLC”), were presented during the IASLC […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China. The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the […]
Date: Thursday, November 16, 2023 Time: 2:30pm GMT (10:30pm HKT/ 9:30am EST) Listen to the the Webcast
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (“GEJ”) […]
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, where it was designated a Breakthrough Therapy — — Results to be submitted to an upcoming medical meeting — Hong Kong, Shanghai & Florham Park, […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 7, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has issued a total of 3,000,000 ordinary shares of US$0.10 each (“Ordinary Shares”) following the exercise of share options by Dr Weiguo Su, Executive Director, Chief Executive Officer and Chief […]
Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which include US$259 million of the upfront recognized from Takeda) Company to Host Interim Results Call & Webcast Today at […]
Date: July 31, 2023 (Monday) Announcement release: 7am EDT / 12 noon BST / 7pm HKT View Announcement Presentation webcast & call: 8am EDT / 1pm BST / 8pm HKT Listen to the Webcast Replay For investors and analysts who wish to join the call by phone, please use the below registration link to […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 20, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with […]
Ms Ling Yang, aged 43, has been a Non-executive Director of the Company since 2023. She has been the managing director of Carlyle and co-head of Carlyle Asia Healthcare since November 2021, in charge of advising in healthcare investment and portfolio activities of Carlyle in China. She is also chairwoman and non-executive director of ADICON […]
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 13, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that with effect from July 13, 2023: (i) Mr […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, July 10, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective allosteric inhibitor targeting Src homology-2 domain-containing protein tyrosine phosphatase-2 (“SHP2”). The first patient received their first dose on July […]
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, June 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: (a) Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 26, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm […]
Apply Now Job Title: CRA Line Manager (AD) Job Title: Clinical Operation Location: Beijing Responsibilities Be responsible for CRA team management and operational management system. Oversees the performance of the CRAs within their specified team. Implements professional development and performance evaluations; Ensures that clinical monitoring activities of their assigned team are performed to […]
Job Title: Clinical Project Manager Location: Shanghai / Beijing / Guangzhou / Nanjing / Hangzhou / Suzhou / Tianjin Primary Function Management of clinical research project. Vendor (CRO, Lab, drug storage, etc.) supervision and management. Liaison with KOLs. Support IND and NDA filing. Quality control of the clinical research projects, such as co-monitoring. Responsibilities Adhere […]
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — Hong Kong, Shanghai, Florham Park, NJ, Osaka, Japan & Cambridge, MA — Friday, June 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) […]
— Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (“BSC”) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer Osaka, Cambridge, MA, Hong Kong, Shanghai & Florham Park, NJ — Thursday, June 15, 2023: – Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, June 9, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to two novel investigational hematological malignancy therapies, HMPL-306 and amdizalisib, will be presented at the upcoming European Hematology Association (“EHA”) Annual Meeting, taking place June 8-11, 2023 in […]
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 5, 2023, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan adopted by HUTCHMED in 2015 (“LTIP”) and share options under the Share Option Scheme adopted by HUTCHMED in […]
Date: Monday, June 12, 2023 Time: 8am PDT (3pm GMT / 11pm HKT ) Watch the Webcast Replay
Date: Thursday, June 8, 2023 Time: 3:30pm EDT (7:30pm GMT // 3:30am HKT on June 9 ) Watch the Live Webcast
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials — OSAKA, Japan, CAMBRIDGE, Massachusetts, HONG KONG, SHANGHAI &, FLORHAM PARK, New Jersey, Friday May 26, 2023 – Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, May 25, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer therapies fruquintinib, surufatinib and HMPL-453 in 21 abstracts that will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, […]
TR-1: Standard form for notification of major holding NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i “>1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: HUTCHMED (China) Limited 1b. Please […]
Date: Tuesday, May 16, 2023 Time: 9am ET / 1pm GMT/ (9pm HKT ) Listen to Webcast replay